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Background: We aimed to examine the expression level of Nucleophosmin (NPM1) protein in colon cancer tissues
and to investigate the potential role of NPM1 in the regulation of cell migration and invasiveness.
Methods: Immunohistochemical assay was performed to examine the expression pattern of NPM1 in 31 groups of
colonic carcinoma samples, including colon tumors, adjacent normal tissues, and matched metastatic lymph nodes
from the same patients. Small interfering RNA technique and exogenous expression of wild type NPM1 methods
were used to further verify the function of NPM1.
Results: High-expression of NPM1 correlates with lymph node metastasis (P= 0.0003) and poor survival rate of
human colon cancer patients (P= 0.017). SiRNA-mediated reduction of NPM1 was also shown to inhibit the
migration and invasiveness of metastatic colon cancer HCT116 cell line. In addition, the exogenous expression of
NPM1 in HT29 cells, a NPM1 low expression and low invasive colon cancer cell line, enhanced cell migration and
invasiveness along with increased cell proliferation.
Conclusions: The current study uncovered the critical role of NPM1 in the regulation of colon cancer cells
migration and invasion, and NPM1 may serve as a potential marker for the prognosis of colon cancer patients.
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The incidence of colon cancer in China has increased in
recent years and has become one of the most common
malignancies, particularly in more developed areas [1].
Surgery and chemotherapy are highly effective for early-
stage colon cancer [2]. However, the five-year survival
rate of advanced colon cancer patients was very poor be-
cause of insensitivity to chemotherapy and more easily
prone to recurrence [3]. Thus, the majority of patients
with advanced-stage colon cancer die of metastasis. Mo-
lecular-targeted therapy has developed recently as a
more effective approach for the treatment of metastatic
colon cancer patients. However, whether the patients
could receive the targeted drug therapy depends on the
molecular profile of their cancer tissues. Until now, only* Correspondence: tjmuzhangfei@yahoo.com.cn; ningzhangtj@gmail.com
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reproduction in any medium, provided the ora few effective targeted drugs are available for targeted
therapy, such as bevacizumab, which binds to VEGF and
inhibits the initiation of new blood vessel growth [4],
and cetuximab, which targets EGFR and prevents the ac-
tivation of cell growth signaling [5]. Screening and
understanding novel genes involved in carcinogenesis or
cancer metastasis is urgently needed to identify putative
molecular targets for cancer therapy.
NPM1 is also called nucleophosmin, numatrin [6] or
NO38 [7]. It consists of 294 amino acids. NPM1 is an
abundant multifunctional nucleolar phosphoprotein,
which shuttles constantly between the nucleus and cyto-
plasm and is involved in several important biological ac-
tivities [8]. Previous studies demonstrated a critical role
of NPM1 in ribosome biogenesis by regulating ribosome
assembly and transporting ribosomal proteins to the
cytoplasm. NPM1 also plays an essential role in cell
growth and proliferation by regulating cell cycle progres-
sion and centrosome duplication [9,10]. Other studies
also showed that NPM1 could regulate the activity ofThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ect binding [11]. NPM1 is also involved in transcription
activation through interaction with transcription factors,
such as c-Myc and NF-κB [12]. In addition, NPM1 also
functions as a molecular chaperone to regulate DNA
histone assembly and proper folding of unfolding pro-
teins [13].
Numerous studies revealed a critical role of NPM1 in
tumorigenesis [14]. Altered NPM1 expression was
observed in many types of tumors, and mutated NPM1
is frequently detected in human hematopoietic malig-
nancies, especially in acute myeloid leukemia (AML)
[15]. Recent research demonstrated that NPM1 may be a
favorable prognosis marker for AML and even a poten-
tial therapeutic target in hematological malignances [16].
In contrast to AML, mutations of NPM1 are rarely
detected in solid tumors. However, over-expression of
NPM1 is often found in many kinds of solid tumors
[17,18]. Accumulative evidence suggested that highly
expressed NPM1 correlated with the stage of tumor pro-
gression and poor prognosis [19]. Although the function
of NPM1 in carcinogenesis has been intensively studied,
the detailed mechanism is largely unknown.
In the current study, the expression pattern of NPM1
in colon cancer tissues and adjacent normal tissues was
examined. Increased expression of NPM1 was also found
to be associated with lymph node metastasis and poor
survival of colon cancer patients. The current study
hypothesized that NPM1 may play a role in cancer cell
migration and invasion. Small interfering RNA (siRNA)
induced the down-regulation of NPM1-inhibited migra-
tion and invasiveness of metastatic colon cancer in the
HCT116 cell line. Furthermore, exogenous expression of
wild-type NPM1 in HT29 cells enhanced cell migration
and invasiveness along with increased cell proliferation.
These results revealed that NPM1 serves as an import-
ant regulator for cancer cell invasion.
Methods
Cancer tissues and immunohistochemistry
Colon cancer tissues, adjacent normal tissues, and
matched metastatic lymph nodes were obtained from
patients diagnosed with colon cancer in Tianjin Medical
University Cancer Institute and Hospital (Tianjin, P. R.
China) between 2000 and 2005. Immunohistochemical
assay was performed as described previously [20]. In
brief, tissue slides were deparaffinized in xylene and
rehydrated with graded ethanol. The slides were heat
induced in sodium citrate buffer for antigen retrieval,
blocked in 3% BSA for 40 min, and incubated with
mouse anti-human NPM1 antibodies (Santa Cruz Bio-
technology, CA, USA) (1:50) at 4°C overnight. Detection
was performed using an HRP-linked secondary antibody
and a DAB kit. The slides were then counterstained withhematoxylin and mounted. Highly expressed NPM1 in
human breast cancer tissue was used as a positive con-
trol. A negative control was prepared by omitting the
primary antibody. The staining intensity and percentage
of positive cells were scored semi-quantitatively by two
pathology doctors. The intensity of staining was classi-
fied into four categories: "0" for no brown particle stain-
ing, "1" for light brown particles, "2" for moderate brown
particles, and "3" for dark brown particles. The percent-
age of positive cells was divided into four groups: "0" for
<10% positive cells, "1" for 10%–40% positive cells, "2"
for 40%–70% positive cells, and "3" for ≥70% positive
cells. The sum of the intensity and percentage of positive
staining was used to determine high (score ≥ 3) or low
(score< 3) expression of NPM1.
Cell culture
Human colon cancer cell lines HCT116 and HT29 was
purchased from Cell Resource Center, Institute of Basic
Medical Sciences, Chinese Academy of Medical
Sciences/Peking Union Medical College (Beijing, China).
HCT116 cells were maintained in Iscove’s Modified Dul-
becco’s medium (IMDM) (Hyclone, USA) supplemented
with 10% fetal bovine serum (FBS, Hyclone, USA),
HT29, SW480, Colo205 and SW620 cells were cultured
in Dulbecco's Modified Eagle Medium supplemented
with 10% FBS and 100U of penicillin and streptomycin
(Hyclone, USA).
Plasmid construction, siRNA and plasmid transfection
NPM1 specific siRNA (Sense: 5' -CCUAGUUCUGUA-
GAAGACAtt-3' and Antisense: 5' -ttUGUCUUCUACA-
GAACUAGGsiRNA-3') was synthesized by Genechem
Co (Shanghai, P. R. China). Full length NPM1 was amp-
lified by PCR with the followed primers: Forward: 5'-
GCGCTCGAGATGGAAGATTCGATGGACATG-3're-
verse: 5'-CGCGAATTCAAGAGACTTCCTCCACTG-3'.
The PCR products were purified, digested and cloned
into pEGFP-C3 vector (BD biosciences Clontech, CA) in
the EcoR I and Xho I site (NEB, USA). The construct
was verified by enzyme digestion and DNA sequencing.
For transfection, human colon cancer cell lines HCT116
and HT29 were cultured to 60% -70% confluence in 6-
well plates, then 100 pmol siRNA duplexes or 4 μg
NPM1 expression plasmids and control vector were
transfected with Lipofectamine 2000 (Invitrogen, Carls-
bad, CA) according to the manufacturer’s instructions.
After transfection for 48 hours, cells were harvested and
used for further assays.
Cell migration and invasion assays
Cell migration and invasion assays were performed as
described previously [21]. Briefly, 48 hours after trans-
fection, control and NPM1 knockdown cells or NPM1
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pended, then 5 × 105 cells in 400 μl serum free medium
was added into the transwell inserts with 8μm pore poly-
carbonate filters which coated with (invasion) or without
matrigel (migration) (BD Biosciences, San Jose, CA).
After 24h (migration) or 48h (invasion) incubation, non-
migrated cells on the top of the membrane were
removed with a cotton swab. Cells migrated to the bot-
tom sides of the membrane were fixed and stained. The
number of migrated cells on the membrane was then
counted in 3 randomly selected fields and taken the pic-
ture under a light microscope (Nikon SMZ 1000) at
400× magnification. All the experiments were performed
at least three times.
MTT assay
Control and siNPM1 colon cancer cells or NPM1 over-
expression cells were plated in a 96-well microplate at
densities of 2000 per well. The cells were cultured con-
tinuously for 4 days, upon analysis, 20μl of MTT reagent
(5 mg/ml, Sigma, USA) was added into each well and
the cells were incubated at 37°C for 4 h. Then the super-
natant was discarded and 150ul of DMSO was added
into each well, after incubation at 37°C for 30min, the
absorbance was measured at 570 nm.
BrdU incorporation assay
Cell proliferation assay was performed using a Cell Pro-
liferation ELISA System (Roche Molecular Biochemicals,
Mannheim, Germany) according to the manufacturer’s
protocol. Cells were seeded onto 96-well plates at a
density of 5000 cells per well and cultured for 24 h.
BrdU solution (10 μM) was added to each well and the
cells were incubated for another 4 h. The cells were then
fixed, denatured, and immunostained with anti-BrdU
antibody. BrdU incorporation was measured using an
ELISA plate reader at 450 nm absorbance.
Immunocytochemistry
Colon cancer cells were grown on sterile slips for 24 h,
washed three times with PBS, and fixed in ice-cold etha-
nol for 10 min. Endogenous peroxidase activity was sup-
pressed by incubation with 3% H2O2 in methanol for 10
min. After blocking with normal serum for 30 min, the
cells were incubated with a working solution containing
mouse anti-human proliferating cell nuclear antigen
(PCNA) antibodies (ZhongShan Co., China) for 2 h at
room temperature. Incubation with HRP-conjugated
secondary antibody for 1 h at 37°C followed. The signal
was detected using a commercial kit (Dako EnVision
System, CA, and USA). The slides were mounted and
observed under a light microscope (Nikon SMZ 1000) at
400× magnification. Five areas were randomly chosen to
count the number of PCNA-positive staining cells.The PCNA staining index was calculated by counting
the number of PCNA-positive staining cells per 100
cells.Wound healing assay
Cells were plated in 35 mm dishes at a density of
7.5 × 105 cells per ml and cultured to form confluent cell
monolayers. Then cells were scraped with a 10 μl pipette
tip and washed with PBS to remove nonadherent cells,
followed by incubation in medium containing 0.5% FBS
at 37°C for 0, 3, 6, 9, 12 and 24 h. The wound areas were
calculated and photographed under a phase contrast mi-
croscopy at 100× magnifications (Olympus CKX41, JP).
The migration distance was quantified by subtracting
the width of the wounds at each time point from the
width of the initial wounds. All experiments were
repeated three times, and the quantitative data were
expressed as mean ± SD.Western blot analysis
Control group and experimental group of cells were pla-
ted on 10cm dish and cultured to 90% confluence. The
cells were washed three times with cold PBS and lysed
in 1x SDS cell lysis buffer containing a protease inhibitor
cocktail (Roche Applied Science, Indianapolis, IN).
Then, the cell lysates were boiled at 95°C for 5 minutes,
cooled on ice, after centrifugation at 12,000g at 4°C for
15 minutes, protein concentration was determined by
using a BCA™ Protein Assay Kit (Thermo, USA). 15ug of
lysates was separated by 10% SDS-PAGE and transferred
onto a PVDF membrane (Millipore, Bedford, MA), then
the membrane was blocked with 5% nonfat milk for 1 h
and incubated with monoclonal mouse anti-human
NPM1 antibody (Santa Cruz, Biotechnology, CA 1:2000)
overnight at 4°C. The membrane was then washed three
times with TBST (TBS + 0.1% Tween-20) and incubated
with a HRP-conjugated secondary antibody for 1 hour at
room temperature, β-actin (Santa Cruz, Biotechnology,
CA) (1:2500) was used as a loading control. An
enhanced chemiluminescence reagents ECL kit (Sigma,
USA) was used to examine the expression of indicated
proteins.Statistical analysis
All data were analyzed by Statistical Package for the So-
cial Sciences (SPSS 17.0 Chicago, IL) and GraphPad
Prism 5 statistical software (San Diego, CA, USA). Chi-
squre test or student’s T-test (two-tailed) and one-way
ANOVA were used for data analysis. The survival curve
of patients was calculated by Kaplan-Meier method. A P
value less than 0.05 was considered statistically
significant.
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High-expression of NPM1 is associated with lymph node
metastasis in colonic carcinoma
The expression level of NPM1 in 31 groups of colonic
carcinoma tissues, including colon tumors, adjacent
normal tissues, and matched metastatic lymph nodes
from the same patients was investigated. Positive stain-
ing was observed in 19 cases of cancer tissues and 23
cases of metastatic lymph nodes. However, positive
staining was observed in only eight cancer-adjacent nor-
mal tissues (Figure. 1A, Table 1). Statistical analysis
showed a high expression of NPM1 correlated with
lymph node metastasis (P= 0.0003), indicating an asso-
ciation between NPM1 in tumorigenesis and cancer me-
tastasis. Among 13 cases of cancer tissues with distant
metastasis, 12 showed positive staining for NPM1.
Among 18 cases of cancer tissues without distant me-
tastasis, only 7 exhibited positive staining (P= 0.003).
These data suggested that the high expression of NPM1
in patients was correlated with increased distant metas-
tasis. A statistically significant correlation was also
observed between high NPM1 expression and poor sur-
vival rate compared with low NPM1 expression
(P= 0.017) (Figure. 1B, Table 2). Thus, high NPM1Figure 1 Increased NPM1 expression was associated with lymph node
Immunohistochemical analysis of NPM1 expression in colon cancer tissues,
the same patients. A primary antibody replaced with PBS was used as a ne
of NPM1 was used as a positive control. B. Kaplan–Meier estimates of the oexpression may be a poor prognosis marker for colon
cancer patients.Expression of NPM1 was elevated in highly invasively
colon cancer cell line
To investigate the relationship between NPM1 and can-
cer cell aggressive, the expression level of NPM1 in five
different colon cancer cell lines with distinct invasive po-
tential was examined using the Western blotting
method. NPM1 was found to be strongly expressed in
the HCT116 cell line, but weakly in the HCT29 cell line,
a low metastatic colon cell line [22-26] (Figure 2A). We
also examined the invasion and migration potential of
five colon cancer cell lines by transwell and the wound
healing assays. As shown in Figures 2D and 2E, transwell
assays showed that HCT116 cells exhibited higher inva-
sion and migration ability than HT29 cells; similarly,
wound healing assay also showed that directional migra-
tion of HCT116 cells was higher than HT29 cells (Fig-
ure 2F). These data were consistent with previous
reports that HCT116 is a highly aggressive cell line
[24,27]. Therefore, NPM1 may play a role in the
enhanced invasiveness of colon cancer cells.metastasis and poor survival rate of colon cancer patients. A.
adjacent normal tissues, and matched metastatic lymph nodes from
gative control, and breast cancer tissue known to express high levels
verall survival rate according to the expression of NPM1 (P= 0.017).
Table 1 Expression of NPM1 in colon cancer tissues,




Adjacent normal tissues 31 8 23
Colon cancer tissues 31 19* 12
Metastatic lymph nodes 31 23# 8
Compared with adjacent normal tissues P = 0.0098; # compared with
adjacent normal tissues P= 0.0003.
Table 2 Correlation of NPM1 expression with
clinicopathologic parameters of colon cancer patients
NPM1 expression
Parameters/Markers Total Negative Positive P-value
Age (year)
<40 4 1 3 0.813
40-60 19 8 11
>60 8 3 5
Sex
Male 13 8 5 0.060
Female 18 4 14
Size(cm)
<4 10 5 5 0.308
≥4 21 7 14
Position
Ascending colon 17 5 12 0.272
Transverse colon 2 1 1
Descending colon 2 0 2
Sigmoid colon 10 6 4
Distant metastasis
Negative 18 11 7 0.003*
Positive 13 1 12
*P< 0.05.
Liu et al. Journal of Biomedical Science 2012, 19:53 Page 5 of 10
http://www.jbiomedsci.com/content/19/1/53Down-regulation of NPM1 inhibited cancer cell
proliferation
Previous studies have demonstrated that NPM1 is over-
expressed in several solid tumors, and contributed to cell
growth and proliferation [17,18,28,29]. The current
study investigated the different proliferation rate of five
colon cancer cell lines in native conditions using the
MTT and BrdU incorporation methods. Cell line
HCT116 with highly expressed NPM1 had a higher pro-
liferation rate than other cells (Figures 2B and 2C). To
validate further the relationship between NPM1 and cell
proliferation, a siRNA sequence was used to knockdown
the expression of NPM1 in colon cancer cells. Compared
with the control siRNA, transient transfection with
NPM1-specific siRNA successfully downregulated
NPM1 expression in HCT116 cells (Figure 3A). The
MTT and BrdU incorporation assay results showed that
cells with NPM1 knockdown exhibited decreased cell
proliferation (Figures 2B and 3C) and decreased PCNA
expression (Figure 3D). This finding indicated that
NPM1 function was inhibited in HCT116 cells, consist-
ent with previous reports [30-32].
Reduction of NPM1 impaired Human colon cancer cell
migration and invasion
The current study speculated that NPM1 may play a role
in the elevated invasive potential of cancer cells and
investigated the effect of NPM1 knockdown on cancer
cell migration and invasion using a Boyden chamber
assay. The current data showed that the migration and
invasiveness of HCT116 cells transfected with NPM1-
specific siRNA significantly decreased compared with
that of the cells transfected with control siRNA ( Add-
itional file 1,Figure 3E ). These results suggested that
NPM1 plays an important role in the migration and in-
vasion of colon cancer cells.
Exogenous expression of NPM1 enhanced migration and
invasion ability of HT29 cells
To further reveal the role of NPM1 in the regulation of
cancer cell migration and invasion, EGFP tagged wild-
type NPM1 construct were transfected into HT29 colon
cells, which exhibited weak migration and invasiveness.Transfection of NPM1 construct in HT29 cells led to
increased expression of NPM1, NPM1 expression in
HT29 cells were also confirmed by Western blotting
using GFP antibodies. As shown in (Figure 4A). Migra-
tion and invasion assay results showed that elevated
NPM1 expression in HT29 cells enhanced cell migration
and invasive ability, compared with that of the cells trans-
fected with empty vectors (Additional file 2,Figure 4E). In
addition, HT29 cells transfected with wild-type NPM1
were also found to display a significant increase in cell
proliferation (Figures 4 B and 4C), meanwhile, PCNA ex-
pression in nucleus was also elevated (Figure 4D).Discussion
NPM1 is a multifunctional nucleolar phosphoprotein
that plays an essential role in cell growth and prolifera-
tion by regulating cell cycle progression,ribosome bio-
genesis, and centrosome duplication [10,33,34]. NPM1 is
also crucial for maintaining genomic stability by influen-
cing DNA replication and repair [35]. The molecular
chaperone activity of NPM1 is critical for DNA-histone
assembly and proper protein folding. In addition, NPM1
is involved in transcription activation through its inter-
action with transcription factors, such as c-Myc, NF-κB,
and FOXM1 [36-38]. Given the fact that NPM1 func-
tions as a key regulator for many cellular activities [35],
Figure 2 Expression of NPM1 was elevated in highly invasive colon cancer cell line HCT116. A. Western blotting analysis of NPM1
expression in five different colon cancer cell lines with distinct invasive potentials; β-actin was used as a loading control. B. Cell proliferation was
measured by the BrdU incorporation assay. The proliferation rates of HCT116 and Colo205 were significantly higher than those of HT29. ***P <
0.0001, **P < 0.001. C. Immunocytochemical staining of PCNA in different cell lines. Expression of PCNA was higher in the HCT116 and Colo205
cell lines than in the HT29 cell line. Picture was taken with a light microscope at 400 magnifications. ***P < 0.0001. D. HCT116 and Colo205 cells
exhibited higher invasive ability than HT29 cells. 5 × 105 cells in 400 ul serum free medium were loaded into transwell inserts with 8μm pore
polycarbonate filters which coated with matrigel. After 48h incubation, the invaded cells on the bottom side of the membrane were fixed and
stained with 0.005% crystal violet. Then,the number of invaded cells was counted in three randomly chosen areas (400 × magnification) and
summarized in the right panel. ***P < 0.0001, **P < 0.001. E. HCT116 and Colo205 cells exhibited higher migration ability than HT29 cells.
Migration assay was performed the same as transwell invasion assay except that there was no coating matrigel on the filters. ***P < 0.0001. F.
Representative images of wound healing assays at 0 and 24 h (100 × migration). The migration distance was quantified by subtracting the width
of the wounds at each time point from the width of the initial wounds. HCT116 cells showed increased migration ability compared with the
other cell lines. ***P < 0.0001.
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much attention. Interestingly, previous studies revealed
that NPM1 acts as both tumor suppressor and proto-
oncogene during tumorigenesis [39]. On one hand,
NPM1 functions as a tumor promoter through the in-
hibition of several tumor suppressors including P53 and
Rb via direct binding. NPM1 can also interact withproto-oncogene c-Myc and enhance its transforming ac-
tivity [11]. On the other hand, NPM1 is a potential
tumor suppressor by maintaining chromosome stability
and regulating ARF activity [40,41].
Numerous studies demonstrated that the contribution
of NPM1 to tumorigenesis depend on its expression
level and genetic modifications [42]. Most studies on
Figure 3 Knock down of NPM1 expression inhibited human colon cancer cell migration, invasion and proliferation. A. Western blotting
analysis of NPM1 expression in HCT116 cells, HCT116 cells transfected with NPM1 specific siRNA and a control siRNA (Scr). β-actin was used as a
loading control. B. MTT assay showed that the knockdown of NPM1 expression inhibited cell proliferation. Data were presented as mean± SD.
***P< 0.0001. C. BrdU incorporation rate decreased after the knockdown of NPM1 in HCT116 colon cancer cells. **P< 0.001. D. PCNA expression
in the nucleus was reduced after the down-regulation of NPM1. The PCNA staining index was calculated by counting the number of PCNA-
positive staining cells per 100 cells in five randomly chosen areas. ***P< 0.0001. E. Knockdown of NPM1 decreased colon cancer cell invasion.
Cell suspension with serum-free medium was loaded into the matrigel-coated upper chamber, and FBS-containing media were loaded into the
lower chamber. The invaded cells were counted in three randomly chosen areas. *P< 0.05.
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cies, and mutations of NPM1 are frequently observed in
these tumors, especially in AML. In contrast to AML, a
recent study found that mutated NPM1 is rarely
detected in solid tumors. Instead, altered expression of
NPM1 was observed in many types of solid tumors, and
the detailed functions are just starting to be clarified
[43]. In the current study, evidence that NPM1 expres-
sion was remarkably increased in the colon cancer tis-
sues and metastatic lymph nodes compared with the
adjacent noncancerous tissues was provided. Statistical
analysis showed that the overexpression of NPM1 was
associated with distant metastasis, suggesting that
NPM1 might play a critical role in colon carcinogenesis
and colon cancer metastasis. Another study also showed
that increased NPM1 expression correlated with tumor
progression in hepatocellular carcinoma [44], which was
consistent with the current result. In addition, a positive
correlation was also found between the high expression
of NPM1 and the poor five-year survival performance of
colon cancer patients. Interestingly, similar results werealso observed in other solid tumors [45,46], indicating
that NPM1 may be a potential prognosis marker for can-
cer patients.
Although much evidence demonstrates that NPM1 ex-
pression correlates with clinical parameters of cancer
patients, the detailed role of NPM1 in cancer progres-
sion is largely unknown. The current finding on the
increased expression of NPM1 in highly metastatic
HCT116 colon cancer cells probably indicate that
NPM1 is involved in colon cancer metastasis, in addition
to cell growth regulation and proliferation. In support of
this hypothesis, the present results showed that siRNA
induced the down-regulation of NPM1-inhibited migra-
tion and invasion of human colon cancer cell HCT116
along with decreased cell proliferation. Furthermore, ex-
ogenous expression of wild-type NPM1 in HT29 cells
enhanced cell migration and invasiveness. Migration and
invasion is critical for cancer cell metastasis, thus, the
current results provided direct evidence that the expres-
sion level of NPM1 is necessary for colon cancer cell
metastasis. Interestingly, a recent study reported that
Figure 4 Exogenous expression of NPM1 enhanced colon cancer cell migration and invasive ability. A. Western blotting analysis of NPM1
expression in HT29 cells transfected with control or GFP-tagged NPM1 plasmid. NPM1 and GFP antibody were used to confirm the expression of
NPM1. β-actin was used as a loading control. B. MTT assay showed that elevated NPM1 expression in human colon cancer HT29 cells increased
cell proliferation. ***P< 0.0001. C. BrdU incorporation rate increased after exogenous NPM1 expression in HT29 cells. **P< 0.001. D. PCNA
expression in the nucleus increased after exogenous NPM1 expression in HT29 cells. ***P< 0.0001. E. Elevated NPM1 expression in human colon
cancer HT29 cells enhanced the cell invasive ability. **P< 0.001.
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NIH3T3 cells [20]. In contrast to this finding, mutations
of NPM1 inhibited cell migration in HEK293 cells [47].
The effect of NPM1 on cell migration may be cell type-
dependent because NPM1 mutations are a rare event in
most solid tumors [46]. However, its detailed role in can-
cer cell metastasis needs further investigation.
Conclusion
The current results suggested that the elevated expres-
sion of NPM1 correlated with distant metastasis and
poor survival of colon cancer patients. The current study
also provided the first direct evidence that the expres-
sion level of NPM1 is critical for colon cancer cell mi-
gration and invasion. Although the detailed mechanism
of NPM1 in colon carcinogenesis remains to beelucidated, the present study speculated that NPM1 may
be a potential prognosis biomarker and a possible thera-
peutic target for colon cancer patients.
Additional files
Additional file 1: Knockdown of NPM1 decreased colon cancer cell
migration. Cell migration assay was performed by using transwell insert
without coating matrigel in the upper chamber; Cell suspension with
serum free media was loaded into upper chamber, and FBS containing
media were loaded into the lower chamber. Then invaded cells in three
random chosen areas were counted. ** P< 0.001.
Additional file 2: Elevated NPM1 expression in human colon cancer
HT29 cells promotes cells migration ability. High expression of NPM1
enhanced migration ability of HT29 cells. * P< 0.05.
Abbreviations
NPM1: Nucleophosmin:; AML: acute myeloid leukemia; PCNA: proliferating
cell nuclear antigen.
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